{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:52:03Z","timestamp":1793317923778,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The gastrointestinal stromal tumors (GIST) are a rare gastrointestinal tract malignancy. The two primary mutation sites are found in KIT and platelet-derived growth factor receptor-\u03b1 (PDGFR-\u03b1) genes. The current study reports on a point mutation within the exon 11 of KIT, named KIT p.V560E. Patient-derived organoids (PDOs) are potential 3D <jats:italic>in vitro<\/jats:italic> models of tissues that can be used to identify sensitivity toward specific targets in patients with tumors and allow for personalized medicine when drugs specific for newly identified genetic locus mutations are not yet available. This study describes a 68-year-old patient who complained of diffused abdominal pain and intermittent melena lasting more than 10 days. He has no other gastrointestinal abnormalities, prior abdominal surgery, or related family history. Surgery was conducted first to remove the lesions and ascertain the disease through histology and immunohistochemical stains of the mass. Immunohistochemistry revealed that the tumor was positive for CD117 and Dog-1. Based on the above findings, he was diagnosed with GISTs. Gene detection analysis and organoid culture were then performed to verify clinical decisions. KIT p.V560E and the reduced number of RB1 copies were identified as two obvious mutations, so the patient was administrated first-line treatment of imatinib 400 mg\/d. However, progressive disease prompted us to switch to sunitinib, and his condition gradually improved. Meanwhile, organoid culture showed sensitivity to sunitinib and tolerance to imatinib with half-maximal inhibitory concentration (IC50) values of 0.89 and &amp;gt;20, respectively. In summary, to the best of our knowledge, this is the first time that the established organoid culture indicated that the GISTs organoid could identify the sensitivity to target therapies and facilitate individual-based treatment.<\/jats:p>","DOI":"10.3389\/fonc.2022.920762","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T05:06:38Z","timestamp":1659416798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-Derived Organoid Facilitating Personalized Medicine in Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Ying","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-016-3196-x","article-title":"Giant Gastric Gastrointestinal Stromal Tumor (GIST)","volume":"21","author":"Navarrete","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i26.2806","article-title":"Current Clinical Management of Gastrointestinal Stromal Tumor","volume":"24","author":"Akahoshi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt158","article-title":"The Primary Extra-Gastrointestinal Stromal Tumor of Pleura: A Case Report and a Literature Review","volume":"43","author":"Yi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079666","article-title":"PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-018-0123-0","article-title":"CD117 is Not Always Positive in Infantile Gastrointestinal Stromal Tumor","volume":"14","author":"He","year":"2018","journal-title":"World J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181a90e1a","article-title":"DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases","volume":"33","author":"Miettinen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050679","article-title":"Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40709.x","article-title":"The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases From 1992 to 2000","volume":"100","author":"Tran","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4261\/1305-3825.DIR.1861-08.2","article-title":"Esophageal Gastrointestinal Stromal Tumor With Pulmonary and Bone Metastases","volume":"16","author":"Ozan","year":"2010","journal-title":"Diagn Interv Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal Stromal Tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors","volume":"29","author":"Adams","year":"2007","journal-title":"Clin Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.08.20","article-title":"Gastrointestinal Stromal Tumors: A Comprehensive Review","volume":"10","author":"Parab","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse Models for Cancer Immunotherapy Research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.bjc.6605117","article-title":"Prognosis and Predictive Value of KIT Exon 11 Deletion in GISTs","volume":"101","author":"Bachet","year":"2009","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001971","article-title":"Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens in Stage IV Colorectal Cancer: A Blinded Study","volume":"64","author":"Wang","year":"2021","journal-title":"Dis Colon Rectum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 Stem Cells Build Crypt-Villus Structures In Vitro Without a Mesenchymal Niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00143","article-title":"Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids","volume":"5","author":"Mauri","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12885-019-5683-4","article-title":"Long-Term Survival of an Elderly Patient With Advanced Gastric Cancer After Combination Therapy: A Case Report and Literature Review","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.02.257","article-title":"Resection of Liver Metastases in Patients With Gastrointestinal Stromal Tumors in the Imatinib Era: A Nationwide Retrospective Study","volume":"42","author":"Seesing","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-132","article-title":"High Tumor Mutation Burden in a Patient With Metastatic Gastric Cancer Sensitive To Trastuzumab: A Case Report","volume":"10","author":"Hu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9037217","article-title":"Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions","volume":"2020","author":"Kreidieh","year":"2020","journal-title":"BioMed Res Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000404","article-title":"Overcoming Resistance to Anti-PD1 and Anti-PD-L1 Treatment in Gastrointestinal Malignancies","volume":"8","author":"Puccini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.11.011","article-title":"GEIS Guidelines for Gastrointestinal Sarcomas (GIST)","volume":"55","author":"Poveda","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22988","article-title":"The Novel KIT Exon 11 Germline Mutation K558N is Associated With Gastrointestinal Stromal Tumor, Mastocytosis, and Seminoma Development","volume":"12","author":"Meir","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"B28","article-title":"Rapid Relapse After Resection of a Sunitinib-Resistant Gastrointestinal Stromal Tumor Harboring a Secondary Mutation in Exon 13 of the C-KIT Gene","volume":"32","author":"Kikuchi","year":"2012","journal-title":"Anticancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182a15eb7","article-title":"Long-Term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial","volume":"258","author":"DeMatteo","year":"2013","journal-title":"Ann Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal Stromal Tumours: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal Stromal Tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-96","article-title":"Motesanib Inhibits Kit Mutations Associated With Gastrointestinal Stromal Tumors","volume":"29","author":"Caenepeel","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812413106","article-title":"KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao2774","article-title":"Patient-Derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.04.039","article-title":"Organoid Technology in Cancer Precision Medicine","volume":"457","author":"Xia","year":"2019","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01026-6","article-title":"The Management of Metastatic GIST: Current Standard and Investigational Therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101654","article-title":"Xenograft and Organoid Model Systems in Cancer Research","volume":"38","author":"Bleijs","year":"2019","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nm0717-796","article-title":"Put to the Test: Organoid-Based Testing Becomes a Clinical Tool","volume":"23","author":"Chakradhar","year":"2017","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.920762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T05:06:41Z","timestamp":1659416801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.920762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.920762"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.920762","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"article-number":"920762"}}